Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Arthritis & Rheumatology (Hoboken, N.J.)|June 22, 2017
Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United StatesJeffrey R Curtis, Fenglong Xie, Christian Smith, et al.
Pediatric Rheumatology Online Journal|August 22, 2021
Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance RegistryTimothy Beukelman, Aimee Lougee, Roland A Matsouaka, et al.
Arthritis Research & Therapy|May 4, 2017
Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approachesSabrina Gmuca, Rui Xiao, Timothy G Brandon, et al.
Arthritis Research & Therapy|September 23, 2016
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritisTimothy Beukelman, Fenglong Xie, John W Baddley, et al.
Pediatric Radiology|April 18, 2007
Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritisAnne Marie Cahill, Sandy S Cho, Kevin M Baskin, et al.
Pediatric Rheumatology Online Journal|April 19, 2017
The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 monthsTimothy Beukelman, Yukiko Kimura, Norman T Ilowite, et al.
Arthritis Care & Research|November 1, 2023
Using Electronic Health Records and Linked Claims Data to Assess New Medication Use and Primary Nonadherence in Rheumatology PatientsTimothy Beukelman, Yujie Su, Fenglong Xie, et al.
Arthritis Care & Research|April 1, 2024
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic ArthritisMelissa L Mannion, Shahla Amin, Stephen Balevic, et al.
Arthritis Care & Research|April 10, 2016
Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic ArthritisNadia J Luca, Heather F Burnett, Wendy J Ungar, et al.
Arthritis Care & Research|November 6, 2014
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patientsJie Zhang, Fenglong Xie, Elizabeth Delzell, et al.
Pageof 13